9
Dec 2025
SIRT3 deficiency worsens eustachian tube dysfunction during middle-ear infection
Middle-ear infections caused by Gram-negative bacteria remain among the most common pediatric illnesses worldwide.
Cancer Research
Strategic Partnerships
Mercury Pharmaceuticals business strategy is to focus on internal research and development strengths to validate product candidates through proof of concept in cancer patients. We offer access to discovery expertise and product candidates in areas of unmet medical need and distinct commercial value.
Mercury Pharmaceuticals is willing to secure partnerships to enhance our combined ability to advance novel science and accelerate the development of differentiated therapeutics. Our broad intellectual property portfolio and unique research approach enable us to be a productive partner for those seeking to advance meaningful therapeutics in cancer biology, translational oncology, and cancer prevention and control studies.
Mercury Pharmaceuticals has a strategic alliance agreement with Aesica Pharmaceuticals to advance the clinical development for the treatment of ovarian cancer and to collaborate on preclinical studies of MP13920 as a treatment for breast cancer based on positive results from a Phase 2 trial of MP13920 in ovarian cancer patients resistant to paclitaxel (Taxol), the standard of care for this disease.
If interested in learning more, please send us a message.
MERCURY trials
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Cancer
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Neuroscience
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
STAY INFORMED!
9
Dec 2025
New arts and wellbeing program supports the social needs of families affected by dementia
A new arts and wellbeing program co-developed by the University of South Australia, Flinders University and the University of Adelaide shows that supporting the social needs of people living with dementia and their carers can help families rediscover connection, confidence and a sense of community.
9
Dec 2025
State-funded multidisciplinary model improves care for adults with neurodevelopmental disorders
Adults with autism spectrum disorder (ASD) and other neurodevelopmental disorders (NDDs) often lose access to specialized care once they age out of pediatric services.
9
Dec 2025
Blinking suppression reveals how the brain filters speech in noisy environments
Blinking is a human reflex most often performed without thinking, like breathing. Although research on blinking is usually related to vision, a new Concordia study examines how blinking is connected to cognitive function such as filtering out background noise to focus on what someone is trying to say to us in a crowded room.
Why Us?
Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.